Abdominal or Transanal TME for Rectal Cancer Therapy

Launched by CANTONAL HOSPITAL OF ST. GALLEN · Jul 9, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating two different surgical methods to treat rectal cancer: transanal total mesorectal excision (TME) and abdominal TME, which includes open, laparoscopic, and robotic surgeries. The main goal is to find out if the transanal method leads to better outcomes in terms of survival rates, fewer complications after surgery, and lower chances of death within 90 days of the operation compared to the abdominal method.

To participate in this study, patients must be adults aged 18 and older who are scheduled for elective total mesorectal excision for rectal cancer. However, those with other types of cancer, incomplete staging, or certain surgical conditions are not eligible. If you join the trial, you will have the opportunity to receive one of these surgical treatments while contributing to important research that could improve care for future patients with rectal cancer. The study is currently recruiting participants of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • all patients receiving elective total mesorectal excision
• Exclusion Criteria:
• • diagnosis other than rectal cancer
• • partial mesorectal excision
• • discontinuity resection (no anastomosis)
• • incomplete Staging
• • metastatic cancer
• • lack of follow-up
• • decline of a retrospective data Analysis
• • age under 18 years